Samsung Galaxy Watch 6 can predict fainting up to 5 minutes ahead

Samsung's Galaxy Watch 6 can predict a common type of fainting episode up to five minutes before it happens, according to a peer-reviewed study published this month. The research, conducted with Chung-Ang University's Gwangmyeong Hospital, achieved 84.6% accuracy in trials on 132 patients. If the feature ever reaches a commercial watch, it could give people prone to sudden blackouts enough time to sit down or call for help — before they hit the floor.

The study

The Galaxy Watch 6's PPG sensor (the optical light-based monitor on the back of the watch) continuously tracks heart rate variability. An AI model processes that data in real time and flags the physiological pattern that precedes vasovagal syncope — the most common form of fainting, triggered by a sharp drop in heart rate and blood pressure. In testing, the system hit a sensitivity of 90% and specificity of 64%, meaning it catches most real episodes but also generates some false alarms. Results are published in the European Heart Journal – Digital Health, Vol 7, Issue 4 — the first peer-reviewed evidence that an off-the-shelf smartwatch can do this at all.

Vasovagal syncope itself is rarely life-threatening, but the fall it causes can be. Fractures and concussions are common outcomes, particularly in older adults. A five-minute warning window is meaningful — it's enough time to lie down, which almost always prevents the episode from escalating.

Not a product — yet

This is proof-of-concept research, not a software update. The feature is not available on any Galaxy Watch model today, and Samsung's syncope study announcement disclosed no rollout timeline or target devices. Before it reaches consumers in the US, Samsung would need separate FDA clearance — the Galaxy Watch 6 already holds FDA clearance for ECG and irregular heart rhythm detection, but syncope prediction would require its own 510(k) or De Novo regulatory pathway. That process typically takes years. For comparison, Apple's AFib History feature went through FDA's Apple AFib MDDT qualification process before it could be marketed as a health tool — Samsung's syncope feature has no equivalent regulatory qualification yet.

What it means

Samsung frames this as a shift toward preventive health rather than reactive care — a direction the broader wearables industry is clearly moving. The company says it plans more collaborations with medical institutions to bring similar capabilities to future devices. Whether this particular study translates into a shipping feature depends entirely on regulatory clearance and Samsung's product roadmap, neither of which has been shared publicly.

For now, the research is a genuine milestone: the first published proof that a mainstream consumer smartwatch can detect an imminent fainting episode before it happens.